Alnylam Pharmaceuticals, Inc.

The stock remains in a long-term correction after a powerful run, still well below its 200-day average and far under the 52-week high. The tape is trying to stabilize near the lower end of the yearly range, but the broader regime is still defensive rather than trend-confirming.

Street sentiment stays constructive, with a Buy consensus and a $434.90 target versus a $268.98 after-hours price. Recent target moves are mixed but still mostly positive, including raises from H.C. Wainwright, Morgan Stanley, and Raymond James, even as a few firms trimmed targets.

The next print carries a mixed but still favorable setup after a 5-for-7 beat rate. EPS estimates point sharply higher over the next few years, with 2027 EPS at $10.57 and 2028 at $13.62, so shareholders should watch whether execution keeps pace with that ramp.

Recent insider activity leans to net selling, but most of the volume is award and exemption-related rather than discretionary trading. The only clear open-market signal is director David Pyott’s cluster of sales on June 1, while several other entries are awards or exempt transactions that read as compensation flow.

Profitability is strong for a biotech, with an 80.8% gross margin, 23.0% operating margin, and 12.6% net margin. Revenue growth is running at 96.4% year over year, and the balance sheet is solid with $2.91 billion in cash versus $1.28 billion of debt, leaving $1.63 billion net cash.

ALNY screens as a premium biotech with a 48.19 P/E and a valuation that still sits above most mature healthcare names. The setup favors investors who want high-margin RNAi growth and can tolerate a stock that trades on execution rather than near-term cash yield.